Next Phase Newsletter

By Candice He, Global Investment Strategist, LSN

ONELIN Capital Corporation is a multi-billion-dollar conglomerate seeking to partner with impressive early-stage lifescience companies interested in working in the Asian market. As a title sponsor of Digital RESI September, Onelin has selected 20 companies to pitch directly to their panel of investors.

This is a powerful opportunity, not only for the selected finalists, but also for the entire RESI community to view and participate as attendees. We encourage all RESI participants to check out these LIVE pitch sessions next week:

September 21, 12:00 PM – 12:50 PM

Onelin PitchBuzz Session 1 – Therapeutics

September 21, 01:00 PM – 01:50 PM

Onelin PitchBuzz Session 2 – Therapeutics

September 23, 12:00 PM – 12:50 PM

Onelin PitchBuzz Session 3 – Medtech Devices

September 23, 01:00 PM – 01:50 PM

Onelin PitchBuzz Session 4 – Healthcare IT/Digital Health

By Rory McCann, Marketing Manager & Conference Producer, LSN

We’ve had a great Digital RESI September partnering conference this week and are excited to announce that the RESI Live Agenda will be accessible until October 14. If you’ve had a full week of meetings and partnering, don’t worry! Our expert investor panels and recorded company pitches will be available for an additional month following the conference.

In addition to panels and pitches, you can still learn about and connect with our sponsor lineup on the RESI Live agenda.  Today, we’d like to introduce Yuhang Capital.

Yuhang Capital aims to cultivate innovation, support entrepreneurs, and ultimately realize the vision of improving human health and creating better life. Headquartered in San Francisco, California, with offices in Hangzhou, China, Yuhang team manages both an USD and a RMB fund across public and private company investments worldwide.

The 2020 Global Bio-Economy Innovation and Entrepreneurship Competition, co-hosted by Yuhang Capital, is dedicated to sourcing and supporting startups in entering and thriving in the Chinese market. To learn more and apply for the competition, please visit Yuhang’s website at www.yuhangcapital.cn.

By Karen Deyo, Senior Investor Research Analyst, LSN

The RESI Featured Company Pitch Session is a great opportunity for companies to showcase their technologies. Companies participating in the FCPS have a dedicated page that features their pitch which is highlighted in the RESI Digital Agenda, as well as on their partnering page. Additionally, companies will have an opportunity to have a live Q&A session with a panel of relevant investors. Of our six pitch sessions, three of them are funded by the NIH, with two sessions featuring companies from the SEED program, and one session featuring companies sponsored by NCI. Check out all of the FCPS companies below, and make sure to check out the live Q&A sessions!

• Therapeutics, Monday, September 14, 12PM EST
• SEED, Monday, September 14, 4PM EST
• Therapeutics, Tuesday, September 15, 12PM EST
• SEED, Tuesday, September 15, 4PM EST
• Medical Device, Wednesday, September 16, 12PM EST
• NCI, Wednesday, September 16, 4PM EST

By Joey Wong, Investor Research Analyst, LSN

Digital RESI September is off to a great start, but we’re not slowing down! We will be hosting a second week of live investor panels. Check out next week’s lineup, and register here for RESI September 2020 to participate in these live panels!

All panels at Digital RESI September are live-streamed. There will be two live panel sessions each day through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more.

Below is the schedule for next week’s live panel sessions:

-An Interview with Onelin Capital

Judy Lee General Manager, Onelin Capital

Candice He Global Investment Strategist, LSN

Life Science Nation (LSN) is pleased to announce that Onelin Capital Corporation will be a Title Sponsor of the upcoming Digital RESI Conference, taking place September 14-16. Onelin Capital, a multi-billion-dollar global conglomerate, is actively seeking life science startups interested in investments and business opportunities in the Asia market. In this interview, Judy Lee, the General Manager of Onelin Capital, will share how Onelin helped its portfolio companies to grow, what kinds of companies Onelin is seeking for future collaboration, and how Onelin is participating in the upcoming RESI.

Candice He (CH): Could you briefly introduce Onelin Capital and its mandate for early-stage life science investments?

Judy Lee (JL): Thank you, Candice. A bit about us, we are a family office backed by a 30+ year real estate global conglomerate with offices in Silicon Valley, Seattle, and Asia. We are active tech investors, meaning that our investments need to be tech-enabled, but tend to be more long-term focused. We invest across various asset classes, including direct investments into early-stage companies from Seed to Series A. Currently, we have close to 30 companies within our portfolio that are direct investments. We also participate in funds, secondaries, SPVs, etc.

For early-stage life science investments, generally, we are interested in companies that are in the analytics, diagnostics, and early prevention space as they tend to be more healthtech-related. However, if the company has a strategic value for us (meaning has an interest in going to Asia), we are still interested in the partnership/investment side.

CH: Could you please share an example or two of the life sciences companies that Onelin Capital has invested in so that our readers can know more about what kinds of companies Onelin is looking for?

JL: Of course! Our venture investment arm is Constellar Ventures. Through Constellar Ventures, we have invested in several healthtech/life sciences companies, including BioTrillion and Patchd Medical.

BioTrillion is developing a mobile health technology platform called BioEngine4D™ to digitally detect drugs and diseases by measuring data from life, analyzing it through computational advancements in machine vision and artificial intelligence, and applying it back for life. Its mission is to enable smart device technology to empower ordinary consumers with extraordinary health abilities.

Patchd Medical leverages deep learning and off-the-shelf wearables to predict the onset of sepsis in high-risk patients who have been discharged from the hospital. Its early studies have shown it can predict sepsis 8 hours earlier, and more accurately, than existing standards of care.

Both companies are healthtech-related and are much needed in the future of healthcare, especially during Covid-19. Both seek to focus on early detection, diagnostics, and remote monitoring.

CH: I noticed both companies applied to the RESI Innovation Challenge for the first time. Does Onelin always help portfolio companies to connect with useful resources and platforms like RESI? In addition to the investments, how does Onelin help portfolio companies to grow?

JL: Every single one of our investments is quite important to us. We are a family office, and our investments become part of this family. We are always open to lending a helping hand to our portfolio companies, including but not limited to connecting our portfolio companies to useful resources, introducing them to our later-stage investors, providing insights if we are able, and aligning them with strategic partners from a business expansion and development perspective. After all, we are an investor, and we want to see them succeed.

CH: As the RESI Title Sponsor, Onelin Capital is selecting 20 companies to join Onelin PitchBuzz FREE of charge. For the readers who are interested in applying, could you tell them what you look for in potential portfolio companies?

JL: Onelin Capital is looking for all life sciences-related companies who are seeking partnerships in the Asia market to work with, and tech-enabled startups for investments. If you are not selected for our PitchBuzz this time, don’t worry! We still want to get in touch with you and explore opportunities working together. Please don’t hesitate to reach out to us at onelinsv@onelincapital.com.

CH: Thank you very much for the interview, Judy.

For our readers who want to know more about Onelin Capital, RSVP for the live investor panel discussion that will be moderated by Judy, at 8 PM EST, September 10. The full panel lineup is as below. Please also check out Onelin’s website at https://www.onelincapital.com/

Moderator:

Judy Lee
General Manager
Onelin Capital

Judy is a veteran in the investment world with 15+ years of both public and private equities experience.  Coupled with years of global marketing experience, Judy is energetic and widely regarded as a growth catalyst with contagious passion. Judy currently serves as Onelin Capital Principal & General Manager, overseeing the entire family office’s operation as well as fund investments.

Judy’s LinkedIn: https://www.linkedin.com/in/thejudylee/

Panelists:

Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation
Daiichi Sankyo

Dr. Weiyong Sun is currently Senior Director, Searching and Evaluation, Global Business Development at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Immunology Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

Yao Li Ho
Senior Director of Business Development
LYFE Capital

Yao Ho is a Senior Director of Business Development at LYFE Capital. Previously, he was a part of Yangtze River Pharmaceutical Group, where he was a BD Manager. At Yangtze River Pharmaceutical Group, he was part of a team that would help the parent organization source, evaluate, coordinate due diligence and negotiate with potential international partners for pharmaceuticals, biologics and medical devices. Yao has also worked at various diagnostics, nanotechnology and digital health startups where he started as an R&D Engineer and was a member of the founding team at other companies. Yao is an MBA graduate from Tsinghua University in partnership with MIT and Bachelor’s in Biomedical Engineering from UC-Irvine with a specialization in bio-photonics and research in microfluidics.

Haolin Sung
Managing Partner
Chaperone Investment

Haolin Sung is the founder and the managing partner at Chaperone Investment, a Taiwan based VC fund focusing on angel and early stage investment in healthcare and biotech sector. He has 10+ years of experience in this field and serves as a board director for several companies including Panlabs, MountainVet, and was the board director at Pharmigene. Mr. Sung also serves in critical roles at several of the Chaperone portfolio companies including Celtech and Caliway to assist these companies in funding and business development/ licensing activities. Prior to Chaperone Investment, Mr. Sung was the director of the direct investment department for Diamond Biofund, the largest Biotech VC in Taiwan and the deputy director of Microbio Biotech Shanghai. He also worked for First Capital Management as a healthcare/biotech industry analyst. Mr. Sung earned his EMBA at Columbia University and London business school and has a B.S. in Biochemistry from Dong Hwa University.

Haruhiko Sugino
Director, Global Business Development
Otsuka Pharmaceuticals

Currently on an expatriate assignment from Japan, Haru Sugino is leading the global scouting activities for Otsuka Pharmaceutical Co., Ltd working closely with Otsuka’s US and EU BD affiliates. Haru is a part of Otsuka’s evaluation and negotiation team, charged with identifying, evaluating, and negotiating transactions to in-license new innovative compounds that address unmet medical needs in CNS/neuro and renal diseases for both global development or for regional development in Japan and Asia. Haru has been with Otsuka for 22 years in various roles, including sales, pre-clinical drug discovery, clinical R&D, commercial, and business development. Haru has a PhD for neuropharmacology, and moved to business development in 2016 after successfully launching a drug in US on which he worked for 10 years from pre-clinical discovery through to commercialization.